1. Overbosch Paper - "Combined Typhoid Fever and Hepatitis A vaccine: Comparison of Immunogenicity and Safety to monovalent vaccine over 3 years". SUMMARY - BACKGROUND, RESULTS, CONCLUSION
Descripción
nil Vaccines Mapa Mental sobre 1. Overbosch Paper - "Combined Typhoid Fever and Hepatitis A vaccine: Comparison of Immunogenicity and Safety to monovalent vaccine over 3 years". SUMMARY - BACKGROUND, RESULTS, CONCLUSION, creado por Celeste Jacobs el 20/04/2017.
1. Overbosch Paper - "Combined Typhoid Fever and
Hepatitis A vaccine: Comparison of Immunogenicity
and Safety to monovalent vaccine over 3 years".
SUMMARY - BACKGROUND, RESULTS, CONCLUSION
safety and immunogenicity were compared
with the monovalent up to 1 month and
after a booster dose at 3 years
healthy adult volunteers GROUP
A=179 GROUP and B=181
subgroups were boosted after 3
years with Viatim GROUP C=56
and GROUP D=46
local and systemic reactions were
recorded for 28 days post
vaccination
seroconversion, seroprotection and
mean antibody concentrations were
measured at at 14, 28 days, 1, 2 and 3
years post vaccination -
it was again
measured at 28
days post booster
dose
SEROCONVERSION is the time period during
which a specific antibody develops and
becomes detectable in the blood. After
seroconversion has occurred, the disease can
be detected in blood tests for the antibody.
SEROPROTECTION: the
protection gained by
vaccination
MEAN ANTIBODY
CONCENTRATIONS: An
antibody titer is a
measurement of how much
antibody an organism has
produced that recognizes a
particular epitope,
expressed as the inverse of
the greatest dilution (in a
serial dilution) that still
gives a positive result.
ELISA is a common means
of determining antibody
titers.
RESULTS
safety profiles were similar
between 2 groups
immediate local reactions were
infrequent in GROUP A and B
reactions were mild
to moderate pain
less frequent
reactions with
mono hep a
antibody concentration to both antigens
were similar in both GROUPS A & B
HEP A - Day 28
GROUP A - 98.7%
HEP A - 3 years
GROUP A - 99.1%
100% protection
after booster
HEP A - Day 28
GROUP B -100%
HEP A - 3 years
GROUP B - 99%
100% protection
after booster
Ty - Day 28
GROUP A 85.2%
Ty - 3 years GROUP A
fell to 32.1%
after booster
increased to 67.3%
Ty - Day 28
GROUP B 84.9%
Ty - 3 years GROUP B
fell to 35.6%
after booster
increased to 69.8%
seroprotection rates HEP A
seroprotection rates TYPHOID
CONCLUSION
combined vaccine Viatim had
equivalent safety and tolerability
compared to monovalent
combined vaccine was as rapidly
immunogenic as monovalent when
given concurrently
a booster dose after 3 years significantly
increased antibody levels
some evidence of
hyporesonsiveness of
the ty response
BACKGROUND
The safety and immunogenicity of
Viatim, (combined hep a (HA) and
typhoid (Vi) vaccine were compared
with the monovalent component
vaccine